Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.
Case Rep Oncol 2018;11:1–5
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2E2Rys4
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Is it feasible to develop an artificial intelligence algorithm that can actually... Read more on AuntMinnieEurope.com Related Reading: ...
-
Posttraumatic radioulnar synostosis (RUS) is a rare event following forearm fractures. Consequences are disabling for patients who suffer fr...
-
Objectives Foundry work is a risk factor for lung cancer; however, the association with welding is unclear, as smoking is common among metal...
-
Security. Let's face it. Software has holes. And hackers love to exploit them. New vulnerabilities appear almost daily. If you have soft...
-
Abstract Salivary gland tumors are rare, comprising less than 3% of all neoplasia of head and neck region. Pleomorphic adenoma is the most ...
-
Background Agricultural work can expose workers to increased risk of heat strain and volume depletion due to repeated exposures to high ambi...
-
Osteoarthritis (OA) is the most prevalent joint disease. Dietary intake of vitamin C relates to a reduction in cartilage loss and OA. This s...
-
Cone beam computerized tomography (CBCT) has been widely used in dental implanting. However, the local hospitals usually don’t have access t...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου